Mammalian cell display and somatic hypermutation in vitro for human antibody discovery

Current Drug Discovery Technologies

Volumn 11, Issue 1, 2014, Pages 56-64

  King, David J ^a   Bowers, Peter M ^a   Kehry, Marilyn R ^a   Horlick, Robert A ^a  

^a AnaptysBio Inc   (United States)

Author keywords

Affinity maturation; AID; Antibody libraries; Cell display; SHM

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; ANTIBODY; B LYMPHOCYTE ANTIBODY; IMMUNOGLOBULIN G;

ANTIBODY LIBRARY; ANTIBODY RESPONSE; ARTICLE; HEK293 CELL LINE; HUMAN; IN VITRO STUDY; MAMMAL CELL; NONHUMAN; PHAGE DISPLAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SOMATIC HYPERMUTATION;

ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; CELL SURFACE DISPLAY TECHNIQUES; CYTIDINE DEAMINASE; HUMANS; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN;

EID: 84900839112     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/15701638113109990037     Document Type: Article

References (63)

1. Choe H, Li W, Wright PL, et al. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 2003; 114: 161-70.
2. Huang CC, Venturi M, Majeed S, et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type I coreceptor-binding site on gp120. Proc Natl Acad Sci (USA) 2004; 101: 2706-11.
3. Xu C, Sui J, Tao H, Zhu Q, Marasco WA. Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-region sulfation, and define CXCR4 antigenic heterogeneity. J Immunol 2007; 179: 2408-18.
4. Taube R, Zhu Q, Xu C, et al. Lentivirus display; stable expression of human antibodies on the surface of human cells and virus particles. PLoS One 2008; 3: E3181.
5. Bradbury ARM, Sidhu S, Dubel S, McCafferty J. Beyond natural antibodies; the power of in vitro display technologies. Nature Biotechnol 2011; 29: 245-54.
6. Persic L, Righi M, Roberts A, Hoogenboom HR, Cattaneo A, Bradbury A. Targeting vectors for intracellular immunization. Gene 1997; 187: 1-8.
7. Vendel MC, Favis M, Snyder WB, et al. Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties. Arch Biochem Biophys 2012; 526: 188-93.
8. Stengelin S, Stamenkovic I, Seed B. Isolation of cDNAs for two distinct human Fc receptors by ligand affinity cloning. EMBO J 1988; 7: 1053-59.
9. Russell SJ, Hawkins RE, Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 1993; 21: 1081-5.
10. Beerli RR, Bauer M, Buser RB, et al. Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci (USA) 2008; 105: 14336-41.
11. Cumbers SJ, Williams GT, Davies SL, et al. Generation and iterative affinity maturation of antibodies in vitro using hypermutating B-cell lines. Nat Biotechnol 2002; 11: 1129-34.
12. Grawunder U, Stitz J. Identification of antigen or ligand specific binding proteins. International patent application WO2009/109368 A1. September 11, 2009.
13. Higuchi K, Araki T, Matsuzaki O, et al. Cell display library for gene cloning of variable regions of human antibodies to hepatitis B surface antigen. J Immunol Methods 1997; 202: 193-204.
14. Ho M, Nagata S, Pastan I. Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci (USA) 2006; 103: 9637-42.
15. Gurney AL, Lazetic ALL, Bond CJ. Methods for identifying and isolating cells expressing a polypeptide. US patent Application US2011/0287979 A1. November 24, 2011.
16. Akamatsu Y, Pakabunto K, Xu Z, Zhang Y, Tsurushita N. Whole IgG surface display on mammalian cells: Application to isolation of neutralizing chicken monoclonal anti-IL-12 antibodies. J Immunol Methods 2007; 327: 40-52.
17. Zhou C, Jacobsen FW, Cai L, Chen Q, Shen WD. Development of a novel mammalian cell surface antibody display platform. MAbs 2010; 2: 508-18.
18. Bowers PM, Horlick RA, Neben TY, et al. Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies. Proc Natl Acad Sci (USA) 2011; 108: 20455-60.
19. Schenk JA, Sellrie F, Böttger V, Menning A, Stöcklein WF, Micheel B. Generation and application of a fluorescein-specific single chain antibody. Biochimie 2007; 89: 1304-11.
20. Urban JH, Schneider RM, Compte M, et al. Selection of functional human antibodies from retroviral display libraries. Nucleic Acids Res 2005; 33: E35.
21. Zauderer M, Smith ES. In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells. US patent application US2008/0167193 A1. July 10, 2008.
22. Gao G, Wu H. Cell display of antibody libraries. US patent 7,790,655. September 7, 2010.
23. Bebbington C. In: Zola H, Ed. Monoclonal antibodies the second generation. Oxford, Bios Scientific, 1995; 165-81.
24. Benton T, Chen T, McEntee M, et al. The use of UCOE vectors in combination with a preadapted serum free, suspension cell line allows for rapid production of large quantities of protein. Cytotechnology 2002; 38: 43-6.
25. Li CZ, Liang ZK, Chen ZR, et al. Identification of HBsAg-specific antibodies from a mammalian cell displayed full-length human antibody library of healthy immunized donor. Cell Mol Immunol 2012; 9: 184-90.
26. Lindner SE, Sugden B. The plasmid replicon of Epstein-Barr virus: Mechanistic insights into efficient, licensed, extrachromosomal replication in human cells. Plasmid 2007; 58: 1-12.
27. Längle-Rouault F, Patzel V, Benavente A, et al. Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus oriP sequences and EBNA1: Implications of the nuclear import of plasmids. J Virol 1998; 72: 6181-5.
28. Yates JL, Guan N. Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. J Virol 1991; 65: 483-8.
29. Horlick RA, Schilling AE, Samama P, et al. Combinatorial gene expression using multiple episomal vectors. Gene 2000; 243: 187-94.
30. King DJ, Horlick RA, Kehry MR, Bowers PM. Unpublished observations.
31. McConnell AD, Do M, Neben TY, et al. Generation of High Affinity Humanized Antibodies Without Making Hybridomas; Immunization Paired with Mammalian Cell Display and in vitro Somatic Hypermutation. PLoS One 2012; 7: E49458
32. Perelson AS, Oster GF. Theoretical studies of clonal selection; minimal antibody repertoire size and reliability of self non-self discrimination. J Theor Biol 1979; 81: 645-70.
33. Perelson AS. Immune network theory. Immunol Rev 1989; 110: 5-33.
34. Boder ET, Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci (USA) 2000; 97: 10701-5.
35. Clark LA, Ganesan S, Papp S, van Vlijmen HW. Trends in antibody sequence changes during the somatic hypermutation process. J Immunol 2006; 177: 333-40.
36. Zheng NY, Wilson K, Jared M, Wilson PC. Intricate targeting of immunoglobulin somatic hypermutation maximizes the efficiency of affinity maturation. J Exp Med 2005; 201: 1467-78.
37. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 2007; 76: 1-22.
38. Peled JU, Kuang FL, Iglesias-Ussel MD, et al. The biochemistry of somatic hypermutation. Annu Rev Immunol 2008; 26: 481-511.
39. Rogozin IB, Diaz M. Cutting edge: DGYW/WRCH is a better predictor of mutability at G:C bases in Ig hypermutation than the widely accepted RGYW/WRCY motif and probably reflects a twostep activation-induced cytidine deaminase-triggered process. J Immunol 2004; 172: 3382-4.
40. Liu M, Duke JL, Richter DJ, et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008; 451: 841-5.
41. Cohen RM, Kleinstein SH, Louzoun Y. Somatic hypermutation targeting is influenced by location within the immunoglobulin V region. Mol Immunol 2011; 48: 1477-83.
42. Wilson PC, de Bouteiller O, Liu YJ, et al. Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes. J Exp Med 1998; 187: 59-70.
43. Reason DC, Zhou J. Codon insertion and deletion functions as a somatic diversification mechanism in human antibody repertoires. Biol Direct 2006; 1: 24.
44. Sale JE, Neuberger MS. TdT-accessible breaks are scattered over the immunoglobulin V domain in a constitutively hypermutating B cell line. Immunity 1998; 9: 859-69.
45. Krause JC, Ekiert DC, Tumpey TM, Smith PB, Wilson IA, Crowe JE Jr. An insertion mutation that distorts antibody binding site architecture enhances function of a human antibody. MBio 2011; 2: E00345-10.
46. Martin A, Scharff MD. Somatic hypermutation of the AID transgene in B and non-B cells. Proc Natl Acad Sci (USA) 2002; 99: 12304-8.
47. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999; 17: 568-72.
48. Hoet RM, Cohen EH, Kent RB, et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining- region diversity. Nat Biotechnol 2005; 23: 344-8.
49. Prassler J, Thiel S, Pracht C, et al. HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems. J Mol Biol 2011; 413: 261-78.
50. Seo H, Masuoka M, Murofushi H, Takeda S, Shibata T, Ohta K. Rapid generation of specific antibodies by enhanced homologous recombination. Nat Biotechnol 2005; 23: 731-5.
51. Lin W, Kurosawa K, Murayama A, Kagaya E, Ohta K. B-cell display-based one-step method to generate chimeric human IgG monoclonal antibodies. Nucleic Acids Res 2011; 39: E14.
52. Kwakkenbos MJ, Diehl SA, Yasuda E, et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 2010; 16: 123-8.
53. Wang L, Jackson WC, Steinbach PA, Tsien RY. Evolution of new nonantibody proteins via iterative somatic hypermutation. Proc Natl Acad Sci (USA) 2004; 101: 16745-9.
54. Majors BS, Chiang GG, Pederson NE, Betenbaugh MJ. Directed evolution of mammalian anti-apoptosis proteins by somatic hypermutation. Protein Eng Des Sel 2012; 25: 27-38.
55. Chen S, Qiu J, Chen C, et al. Affinity maturation of anti-TNFalpha scFv with somatic hypermutation in non-B cells. Protein Cell. 2012; 3: 460-9.
56. Horlick RA, Macomber JL, Bowers PM, et al. Concomitant Cell Surface Display and Secretion of Proteins from Mammalian Cells Facilitates Efficient in vitro Evolution, Selection and Maturation of Antibodies. J Biol Chem 2013; 288: 19861-9.
57. McConnell AD, Spasojevich V, Macomber JL, et al. An integrated approach to extreme thermostabilization and affinity maturation of an antibody. Protein Eng Des Sel 2013; 26: 151-64.
58. Briney BS, Willis JR, Crowe JE Jr. Location and length distribution of somatic hypermutation-associated DNA insertions and deletions reveals regions of antibody structural plasticity. Genes Immun 2012; 13: 523-9.
59. Yin J, Beuscher AE 4th, Andryski SE, Stevens RC, Schultz PG. Structural plasticity and the evolution of antibody affinity and specificity. J Mol Biol 2003; 330: 651-6.
60. Bouvet JP, Dighiero G. From natural polyreactive autoantibodies to à la carte monoreactive antibodies to infectious agents: Is it a small world after all Infect Immun. 1998; 66: 1-4.
61. Oppezzo P, Dumas G, Bouvet JP, et al. Somatic mutations can lead to a loss of superantigenic and polyreactive binding. Eur J Immunol. 2004; 34: 1423-32.
62. Bostrom J, Yu SF, Kan D, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323: 1610-4.
63. Schaefer G, Haber L, Crocker LM, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20: 472-86.